RUC. Repositorio da Universidade da Coruña
Publication
Artículo científico (JournalArticle)
Development And Characterization Of A Tacrolimus/hydroxypropyl-β-cyclodextrin Eye Drop
[Abstract] Uveitis is a vision inflammatory disorder with a high prevalence in developing countries. Currently, marketed treatments remain limited and reformulation is usually performed to obtain a tacrolimus eye drop as a therapeutic alternative in corticosteroid-refractory eye disease. The aim of this work was to develop a mucoadhesive, non-toxic and stable topical ophthalmic formulation that can be safely prepared in hospital pharmacy departments. Four different ophthalmic formulations were prepared based on the tacrolimus/hydroxypropyl-β-cyclodextrin (HPβCD) inclusion complexes’ formation. Phase solubility diagrams, Nuclear Magnetic Resonance (NMR) and molecular modeling studies showed the formation of 1:1 and 1:2 tacrolimus/HPβCD inclusion complexes, being possible to obtain a 0.02% (w/v) tacrolimus concentration by using 40% (w/v) HPβCD aqueous solutions. Formulations also showed good ophthalmic properties in terms of pH, osmolality and safety. Stability studies proved these formulations to be stable for at least 3 months in refrigeration. Ex vivo bioadhesion and in vivo ocular permanence showed good mucoadhesive properties with higher ocular permanence compared to the reference pharmacy compounding used in clinical settings (t1/2 of 86.2 min for the eyedrop elaborated with 40% (w/v) HPβCD and Liquifilm® versus 46.3 min for the reference formulation). Thus, these novel eye drops present high potential as a safe alternative for uveitis treatment, as well as a versatile composition to include new drugs intended for topical ophthalmic administration., This research was partially supported by the Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100), the ISCIII (PI17/00940, RETICS Oftared, RD16/0008/0003 and RD12/0034/0017) and by Xunta de Galicia, grant numbers GPC2013/015 and GRC2017/015. X.G.-O. and R.V.-F. acknowledge the financial support of the IDIS (Health Research Institute of Santiago de Compostela) (predoctoral research fellowships). P.A. acknowledges the support of RYC-2015/17430 (Ramón y Cajal). A.F.-F. acknowledges the support received from the Instituto de Salud Carlos III (ISCIII) through its Juan Rodes grant (JR18/00014)., Xunta de Galicia; GPC2013/015, Xunta de Galicia; GRC2017/015
Project:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-099597-B-I00
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013–2016 PI17-00940
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RD16-0008-0003
,
MINECO / Plan Nacional de I+D+i 2008-2011 RD12-0034-0017
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RYC-2015-17430
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 JR18-00014
View at: https://hdl.handle.net/2183/46797